Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.77
INCY's Cash to Debt is ranked higher than
55% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. INCY: 0.77 )
INCY' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 0.77

Equity to Asset -0.31
INCY's Equity to Asset is ranked lower than
53% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INCY: -0.31 )
INCY' s 10-Year Equity to Asset Range
Min: -0.95   Max: 0.84
Current: -0.31

-0.95
0.84
F-Score: 4
Z-Score: 2.29
M-Score: -2.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.54
INCY's Operating margin (%) is ranked higher than
78% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. INCY: -4.54 )
INCY' s 10-Year Operating margin (%) Range
Min: -6050   Max: 9.05
Current: -4.54

-6050
9.05
Net-margin (%) -23.43
INCY's Net-margin (%) is ranked higher than
75% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. INCY: -23.43 )
INCY' s 10-Year Net-margin (%) Range
Min: -5750   Max: 7.67
Current: -23.43

-5750
7.67
ROA (%) -13.21
INCY's ROA (%) is ranked higher than
74% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. INCY: -13.21 )
INCY' s 10-Year ROA (%) Range
Min: -76.99   Max: 3.47
Current: -13.21

-76.99
3.47
ROC (Joel Greenblatt) (%) -59.97
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. INCY: -59.97 )
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5697.03   Max: 292.44
Current: -59.97

-5697.03
292.44
Revenue Growth (%) 19.50
INCY's Revenue Growth (%) is ranked higher than
89% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. INCY: 19.50 )
INCY' s 10-Year Revenue Growth (%) Range
Min: -61.4   Max: 454
Current: 19.5

-61.4
454
EPS Growth (%) 29.10
INCY's EPS Growth (%) is ranked higher than
94% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. INCY: 29.10 )
INCY' s 10-Year EPS Growth (%) Range
Min: -45.1   Max: 64.9
Current: 29.1

-45.1
64.9
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

INCY Guru Trades in Q2 2013

Jim Simons 102,800 sh (+22.09%)
Vanguard Health Care Fund 3,807,443 sh (+21.52%)
Mariko Gordon 14,000 sh (unchged)
Steven Cohen Sold Out
Mariko Gordon 168,685 sh (-1.06%)
Manning & Napier Advisors, Inc 430,920 sh (-45.47%)
» More
Q3 2013

INCY Guru Trades in Q3 2013

Steven Cohen 98,391 sh (New)
Vanguard Health Care Fund 3,807,443 sh (unchged)
Mariko Gordon 162,214 sh (-3.84%)
Manning & Napier Advisors, Inc 209,810 sh (-51.31%)
Jim Simons 44,700 sh (-56.52%)
» More
Q4 2013

INCY Guru Trades in Q4 2013

Paul Tudor Jones 5,423 sh (New)
Vanguard Health Care Fund 4,457,643 sh (+17.08%)
Steven Cohen 107,338 sh (+9.09%)
Jim Simons Sold Out
Manning & Napier Advisors, Inc 202,580 sh (-3.45%)
Mariko Gordon 128,959 sh (-20.5%)
» More
Q1 2014

INCY Guru Trades in Q1 2014

Manning & Napier Advisors, Inc Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INCY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2013-12-31 Reduce -20.5%0.06%$34.71 - $51.34 $ 49.3214%128959
Vanguard Health Care Fund 2013-06-30 Add 21.52%0.05%$19.07 - $24.49 $ 49.32126%3807443
Vanguard Health Care Fund 2013-03-31 New Buy0.29%$16.61 - $24.95 $ 49.32141%3133100
George Soros 2011-03-31 Sold Out $13.37 - $16.56 $ 49.32235%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Incyte Corp Ltd

Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Pandora Media Inc, Incyte Corp Ltd, Google Inc, and American Airlines Group Inc. Read more...

Ratios

vs
industry
vs
history
P/S 20.00
INCY's P/S is ranked lower than
60% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. INCY: 20.00 )
INCY' s 10-Year P/S Range
Min: 4.32   Max: 209.75
Current: 20

4.32
209.75
PFCF 681.60
INCY's PFCF is ranked lower than
76% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. INCY: 681.60 )
INCY' s 10-Year PFCF Range
Min: 7.24   Max: 960.86
Current: 681.6

7.24
960.86
EV-to-EBIT 333.30
INCY's EV-to-EBIT is ranked lower than
85% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. INCY: 333.30 )
INCY' s 10-Year EV-to-EBIT Range
Min: 79.8   Max: 2896.5
Current: 333.3

79.8
2896.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.90
INCY's Price/Median PS Value is ranked higher than
80% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. INCY: 0.90 )
INCY' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 15.77
Current: 0.9

0.15
15.77
Earnings Yield (Greenblatt) 0.30
INCY's Earnings Yield (Greenblatt) is ranked lower than
74% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. INCY: 0.30 )
INCY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 1.3
Current: 0.3

0.3
1.3
Forward Rate of Return (Yacktman) -1.10
INCY's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. INCY: -1.10 )
INCY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.6   Max: -1.3
Current: -1.1

-6.6
-1.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany
Incyte Corp Ltd was incorporated in Delaware in 1991. It is a biopharmaceutical company which discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs. The Company's most advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA) as a treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. MF is a serious, life-threatening blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms that include polycythemia vera and essential thrombocythemia. JAKAFI is the first FDA-approved JAK inhibitor, and is part of a potentially important new oral drug class to treat cancer and chronic inflammatory diseases. The JAK pathway, which consists of four tyrosine kinases—JAK1, JAK2, JAK3 and Tyk2, is dysregulated in many oncologic and inflammatory conditions. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company. The Company's drug discovery and development activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its product candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide